Cargando…

Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

SIMPLE SUMMARY: Most hereditary ovarian cancer is associated with BRCA1/2 variants, and risk-reducing salpingo-oophorectomy during the follow-up monitoring of ovarian cancer development in heathy women with the BRCA1/2 variant reduces ovarian cancer incidence. The aim of this study was to identify p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Hee-Sung, Ho, Jung Yoon, Yu, Jiyoung, Yeom, Jeonghun, Lee, Sanha, Hur, Soo Young, Jung, Yuyeon, Kim, Kyunggon, Choi, Youn Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150736/ https://www.ncbi.nlm.nih.gov/pubmed/34064977 http://dx.doi.org/10.3390/cancers13102300

Ejemplares similares

Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer
por: Liu, Jingjing, et al.
Publicado: (2021)

Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer
por: Jung, Yuyeon, et al.
Publicado: (2021)

Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation
por: Kim, Soo Han, et al.
Publicado: (2021)

Generating Detailed Spectral Libraries for Canine Proteomes Obtained from Serum and Urine
por: Ahn, Hee-Sung, et al.
Publicado: (2023)

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks
por: Kim, Eun Young, et al.
Publicado: (2020)

Differential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers
por: Yoo, Jigeun, et al.
Publicado: (2020)

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer
por: Han, Mi-Ryung, et al.
Publicado: (2020)

The Function of Drosophila USP14 in Endoplasmic Reticulum Stress and Retinal Degeneration in a Model for Autosomal Dominant Retinitis Pigmentosa
por: Park, Jung-Eun, et al.
Publicado: (2020)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Radiation‐induced C‐reactive protein triggers apoptosis of vascular smooth muscle cells through ROS interfering with the STAT3/Ref‐1 complex
por: Ryu, Je‐Won, et al.
Publicado: (2022)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
por: Whittemore, A S, et al.
Publicado: (2004)

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
por: Biglia, Nicoletta, et al.
Publicado: (2016)

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
por: Mitchell, Rachel, et al.
Publicado: (2018)

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity
por: Sajjad, Monique, et al.
Publicado: (2017)

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers
por: Lee, Eun-Gyeong, et al.
Publicado: (2019)

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Zaman, Tasnim, et al.
Publicado: (2019)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Discovery of urine biomarkers for lupus nephritis via quantitative and comparative proteome analysis
por: Kwon, Oh Chan, et al.
Publicado: (2021)

Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers
por: Dilawari, A, et al.
Publicado: (2008)

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
por: Møller, Pål, et al.
Publicado: (2007)

Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?
por: Ben-Aharon, Irit, et al.
Publicado: (2018)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients
por: Park, Boyoung, et al.
Publicado: (2017)

Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer
por: Nañez, Andrea, et al.
Publicado: (2021)

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
por: Kuchenbaecker, Karoline B., et al.
Publicado: (2017)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
por: Barnes, Daniel R., et al.
Publicado: (2020)

Comparative analysis of therapeutic effects between medium cut-off and high flux dialyzers using metabolomics and proteomics: exploratory, prospective study in hemodialysis
por: Kim, Hyo Jin, et al.
Publicado: (2021)

Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring
por: Kim, Hyunsoo, et al.
Publicado: (2013)

Ovarian tumor diagnosis using deep convolutional neural networks and a denoising convolutional autoencoder
por: Jung, Yuyeon, et al.
Publicado: (2022)

Author Correction: Ovarian tumor diagnosis using deep convolutional neural networks and a denoising convolutional autoencoder
por: Jung, Yuyeon, et al.
Publicado: (2023)

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
por: Lewis, Kelsey E., et al.
Publicado: (2018)

Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers
por: Pejovic, Tanja, et al.
Publicado: (2020)

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers
por: Li, Ang, et al.
Publicado: (2022)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lohmdua7lj0mc9uaj5sah9cmqm